These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30905169)

  • 1. A biocompatible reverse thermoresponsive polymer for ocular drug delivery.
    Balachandra A; Chan EC; Paul JP; Ng S; Chrysostomou V; Ngo S; Mayadunne R; van Wijngaarden P
    Drug Deliv; 2019 Dec; 26(1):343-353. PubMed ID: 30905169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration.
    Luaces-Rodríguez A; Mondelo-García C; Zarra-Ferro I; González-Barcia M; Aguiar P; Fernández-Ferreiro A; Otero-Espinar FJ
    Int J Pharm; 2020 Jan; 573():118767. PubMed ID: 31669558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chitosan-Polycaprolactone Core-Shell Microparticles for Sustained Delivery of Bevacizumab.
    Jiang P; Jacobs KM; Ohr MP; Swindle-Reilly KE
    Mol Pharm; 2020 Jul; 17(7):2570-2584. PubMed ID: 32484677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
    Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
    Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
    Xu Y; Tan CS
    Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
    Rusu IM; Deobhakta A; Yoon D; Lee M; Slakter JS; Klancnik JM; Thompson D; Freund KB
    Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Bioactive Aflibercept In Vitro.
    Liu W; Lee BS; Mieler WF; Kang-Mieler JJ
    Curr Eye Res; 2019 Mar; 44(3):264-274. PubMed ID: 30295090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy.
    Yannuzzi NA; Patel SN; Bhavsar KV; Sugiguchi F; Freund KB
    Am J Ophthalmol; 2014 Aug; 158(2):319-327.e2. PubMed ID: 24814167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
    Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
    Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
    Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
    Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET study of ocular and blood pharmacokinetics of intravitreal bevacizumab and aflibercept in rats.
    Luaces-Rodríguez A; Del Amo EM; Mondelo-García C; Gómez-Lado N; Gonzalez F; Ruibal Á; González-Barcia M; Zarra-Ferro I; Otero-Espinar FJ; Fernández-Ferreiro A; Aguiar P
    Eur J Pharm Biopharm; 2020 Sep; 154():330-337. PubMed ID: 32659326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
    Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
    Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
    Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
    Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Effect of Anti-VEGF Agents on Intraocular Pressure in Age-Related Macular Degeneration.
    Beato J; Pedrosa AC; Pinheiro-Costa J; Freitas-da-Costa P; Falcão MS; Melo A; Estrela-Silva S; Falcão-Reis F; Carneiro ÂM
    Ophthalmic Res; 2016; 56(1):30-4. PubMed ID: 27046391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.
    Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S
    BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept as a Second Line Therapy for Neovascular Age Related Macular Degeneration in Israel (ASLI) study.
    Tiosano L; Segal O; Mathalone N; Pollack A; Ehrlich R; Klemperer I; Barak Y; Moroz I; Chowers I; Goldstein M
    Eye (Lond); 2017 Jun; 31(6):890-898. PubMed ID: 28211882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration.
    Yamashita M; Matsumoto M; Hayakawa M; Sakai K; Fujimura Y; Ogata N
    Sci Rep; 2018 Jan; 8(1):1491. PubMed ID: 29367644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study.
    Kim JH; Lee DW; Chang YS; Kim JW; Kim CG
    Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2101-2109. PubMed ID: 27230919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.